» Articles » PMID: 34199020

Epigenetic Deregulation of Apoptosis in Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jul 2
PMID 34199020
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells possess the ability to evade apoptosis. Genetic alterations through mutations in key genes of the apoptotic signaling pathway represent a major adaptive mechanism of apoptosis evasion. In parallel, epigenetic changes via aberrant modifications of DNA and histones to regulate the expression of pro- and antiapoptotic signal mediators represent a major complementary mechanism in apoptosis regulation and therapy response. Most epigenetic changes are governed by the activity of chromatin modifying enzymes that add, remove, or recognize different marks on histones and DNA. Here, we discuss how apoptosis signaling components are deregulated at epigenetic levels, particularly focusing on the roles of chromatin-modifying enzymes in this process. We also review the advances in cancer therapies with epigenetic drugs such as DNMT, HMT, HDAC, and BET inhibitors, as well as their effects on apoptosis modulation in cancer cells. Rewiring the epigenome by drug interventions can provide therapeutic advantage for various cancers by reverting therapy resistance and leading cancer cells to undergo apoptotic cell death.

Citing Articles

Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.

Zahoor A, Khazer R, Mehraj I, Gani U, Fayaz F, Khanday F Funct Integr Genomics. 2025; 25(1):50.

PMID: 40024973 DOI: 10.1007/s10142-025-01552-x.


Unveiling the link between chronic inflammation and cancer.

Tripathi S, Sharma Y, Kumar D Metabol Open. 2025; 25:100347.

PMID: 39876904 PMC: 11772974. DOI: 10.1016/j.metop.2025.100347.


Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target.

Goyal K, Afzal M, Altamimi A, Babu M, Ballal S, Kaur I Biogerontology. 2024; 26(1):32.

PMID: 39725742 DOI: 10.1007/s10522-024-10173-z.


Combinatorial phenethyl isothiocyanate and withaferin A targets multiple epigenetics pathways to inhibit MCF-7 and MDA-MB-231 human breast cancer cells.

Rahman M, Tollefsbol T Cancer Cell Int. 2024; 24(1):422.

PMID: 39707321 PMC: 11662855. DOI: 10.1186/s12935-024-03619-4.


Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review.

Saxena R, Welsh C, He Y Front Cell Dev Biol. 2024; 12:1462339.

PMID: 39620145 PMC: 11604647. DOI: 10.3389/fcell.2024.1462339.


References
1.
Willis S, Adams J . Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 2005; 17(6):617-25. PMC: 2930980. DOI: 10.1016/j.ceb.2005.10.001. View

2.
Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

3.
Teng S, Ma C, Yu Y, Yi C . Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells. Biosci Rep. 2019; 39(5). PMC: 6522705. DOI: 10.1042/BSR20190456. View

4.
Wu J, Wood G . Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2010; 147(4):443-9. DOI: 10.1001/archdermatol.2010.376. View

5.
Byun D, Cho K, Ryu B, Lee M, Kang M, Kim H . Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003; 63(21):7068-75. View